Profound Medical Corp. (PROF)
기업 설명
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada.

| 국가 | Canada |
| IPO 일자 | 2019년 10월 29일 |
| 산업 | Medical Devices |
| 섹터 | Healthcare |
| 직원 수 | 162 |
| CEO | Dr. Arun Swarup Menawat MBA, Ph.D. |
연락처
주소: 2400 Skymark Avenue Mississauga, ON Canada | |
| 웹사이트 | https://www.profoundmedical.com |
주식 정보
| 티커 | PROF |
| 거래소 | NasdaqCM |
| 회계연도 | Jan '25 - Dec '25 |
| 보고 통화 | USD |
| CIK 코드 | 0001628808 |
| CUSIP 번호 | n/a |
| ISIN 번호 | n/a |
| 고용주 식별번호 | n/a |
| SIC 코드 | n/a |
주요 임원
| 이름 | 직책 |
|---|---|
| Dr. Arun Swarup Menawat MBA, Ph.D. | Chairman of the Board & CEO |
| Dr. Mathieu Burtnyk Ph.D. | President |
| Mr. Rashed Dewan | Chief Financial Officer |
| Mr. Thomas Tamberrino MBA | Chief Commercial Officer |
| Mr. Stephen Kilmer | Investor Relations |
| Mr. Matthew Sobczyk C.A., CPA | Assistant Corporate Controller |
| Mr. Levant Tinaz | Software Developer |
